{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:31:25Z","timestamp":1789191085265,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["13XP5049A"],"award-info":[{"award-number":["13XP5049A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031B0831"],"award-info":[{"award-number":["031B0831"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004581","name":"Brandenburger Staatsministerium f\u00fcr Wissenschaft, Forschung und Kultur","doi-asserted-by":"publisher","award":["F241-03-FhG\/005\/001"],"award-info":[{"award-number":["F241-03-FhG\/005\/001"]}],"id":[{"id":"10.13039\/501100004581","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fraunhofer-Institut f\u00fcr Zelltherapie und Immunologie IZI, Institutsteil Bioanalytik und Bioprozesse des Fraunhofer IZI-BB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With more than 20 Food and Drug Administration (FDA)-approved poly (ethylene glycol) (PEG) modified drugs on the market, PEG is the gold standard polymer in bioconjugation. The coupling improves stability, efficiency and can prolong blood circulation time of therapeutic proteins. Even though PEGylation is described as non-toxic and non-immunogenic, reports accumulate with data showing allergic reactions to PEG. Since PEG is not only applied in therapeutics, but can also be found in foods and cosmetics, anti-PEG-antibodies can occur even without a medical treatment. Hypersensitivity to PEG thereby can lead to a reduced drug efficiency, fast blood clearance and in rare cases anaphylactic reactions. Therefore, finding alternatives for PEG is crucial. In this study, we present linear polyglycerol (LPG) for bioconjugation as an alternative polymer to PEG. We report the conjugation of LPG and PEG by click-chemistry to the glycoprotein erythropoietin (EPO), synthesized in a eukaryotic cell-free protein synthesis system. Furthermore, the influence of the polymers on EPOs stability and activity on a growth hormone dependent cell-line was evaluated. The similar characteristics of both bioconjugates show that LPGylation can be a promising alternative to PEGylation.<\/jats:p>","DOI":"10.1038\/s41598-023-33463-x","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T12:02:58Z","timestamp":1681905778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["One to one comparison of cell-free synthesized erythropoietin conjugates modified with linear polyglycerol and polyethylene glycol"],"prefix":"10.1038","volume":"13","author":[{"given":"Paria","family":"Pouyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zemella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Schlo\u00dfhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben M.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kubick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"33463_CR1","first-page":"518","volume":"19","author":"J Ga\u0161per\u0161i\u010d","year":"2021","unstructured":"Ga\u0161per\u0161i\u010d, J., Kristan, A., Kunej, T., Zupan, I. P. & Debeljak, N. Erythrocytosis: Genes and pathways involved in disease development. Blood Transf. 19, 518\u2013532 (2021).","journal-title":"Blood Transf."},{"key":"33463_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.743926","volume":"13","author":"Y Ma","year":"2022","unstructured":"Ma, Y., Zhou, Z., Yang, G.-Y., Ding, J. & Wang, X. The effect of erythropoietin and its derivatives on ischemic stroke therapy: A comprehensive review. Front. Pharmacol. 13, 743926 (2022).","journal-title":"Front. Pharmacol."},{"key":"33463_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/JCMA.0000000000000175","volume":"82","author":"S-F Tsai","year":"2019","unstructured":"Tsai, S.-F. & Tarng, D.-C. Anemia in patients of diabetic kidney disease. J. Chin. Med. Assoc. JCMA 82, 752\u2013755 (2019).","journal-title":"J. Chin. Med. Assoc. JCMA"},{"key":"33463_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0299-y","volume":"51","author":"JW Lee","year":"2019","unstructured":"Lee, J. W., Ko, J., Ju, C. & Eltzschig, H. K. Hypoxia signaling in human diseases and therapeutic targets. Exp. Mol. Med. 51, 1\u201313 (2019).","journal-title":"Exp. Mol. Med."},{"key":"33463_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.yexcr.2018.12.013","volume":"374","author":"T Annese","year":"2019","unstructured":"Annese, T., Tamma, R., Ruggieri, S. & Ribatti, D. Erythropoietin in tumor angiogenesis. Exp. Cell Res. 374, 266\u2013273 (2019).","journal-title":"Exp. Cell Res."},{"key":"33463_CR6","doi-asserted-by":"publisher","first-page":"175909141987142","DOI":"10.1177\/1759091419871420","volume":"11","author":"F Rey","year":"2019","unstructured":"Rey, F. et al. Erythropoietin as a neuroprotective molecule: An overview of its therapeutic potential in neurodegenerative diseases. ASN Neuro 11, 1759091419871420 (2019).","journal-title":"ASN Neuro"},{"key":"33463_CR7","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/ndt\/gfh106","volume":"19","author":"R Brunkhorst","year":"2004","unstructured":"Brunkhorst, R. et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol. Dial. Transpl. 19, 1224\u20131230 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"33463_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2165\/00003495-200868080-00009","volume":"68","author":"MP Curran","year":"2008","unstructured":"Curran, M. P. & McCormack, P. L. Methoxy polyethylene glycol-epoetin beta: A review of its use in the management of anaemia associated with chronic kidney disease. Drugs 68, 1139\u20131156 (2008).","journal-title":"Drugs"},{"key":"33463_CR9","first-page":"11","volume":"69","author":"N Nand","year":"2021","unstructured":"Nand, N., Nandan, R. & Jain, D. Comparative effects of pegylated erythropoietin and darbepoetin alfa on erythropoietin hyporesponsive anemia of patients with chronic kidney disease on maintenance hemodialysis. J. Assoc. Phys. India 69, 11\u201312 (2021).","journal-title":"J. Assoc. Phys. India"},{"key":"33463_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2217\/nnm.11.19","volume":"6","author":"JV Jokerst","year":"2011","unstructured":"Jokerst, J. V., Lobovkina, T., Zare, R. N. & Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy. Nanomed. (Lond.) 6, 715\u2013728 (2011).","journal-title":"Nanomed. (Lond.)"},{"key":"33463_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10989-019-09840-4","volume":"26","author":"AM Ramos-de-la-Pe\u00f1a","year":"2019","unstructured":"Ramos-de-la-Pe\u00f1a, A. M. & Aguilar, O. Progress and challenges in PEGylated proteins downstream processing: A review of the last 8 years. Int. J. Pept. Res. Ther. 26, 333\u2013348 (2019).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"33463_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112502","volume":"146","author":"T-C Chang","year":"2022","unstructured":"Chang, T.-C., Chen, B.-M., Wu, J.-Y., Cheng, T.-L. & Roffler, S. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice. Biomed. Pharmacother. 146, 112502 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"33463_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1689","volume":"13","author":"A Grigoletto","year":"2021","unstructured":"Grigoletto, A., Tedeschini, T., Canato, E. & Pasut, G. The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules. Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol. 13, e1689 (2021).","journal-title":"Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol."},{"key":"33463_CR14","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"B-M Chen","year":"2021","unstructured":"Chen, B.-M., Cheng, T.-L. & Roffler, S. R. Polyethylene glycol immunogenicity: Theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano 15, 14022\u201314048 (2021).","journal-title":"ACS Nano"},{"key":"33463_CR15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1590\/s2175-97902018000001009","volume":"54","author":"JHPM Santos","year":"2018","unstructured":"Santos, J. H. P. M., Torres-Obreque, K. M., Meneguetti, G. P., Amaro, B. P. & Rangel-Yagui, C. O. Protein PEGylation for the design of biobetters: From reaction to purification processes. Braz. J. Pharm. Sci. 54, 978 (2018).","journal-title":"Braz. J. Pharm. Sci."},{"key":"33463_CR16","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","volume":"33","author":"C Lubich","year":"2016","unstructured":"Lubich, C. et al. The mystery of antibodies against polyethylene glycol (PEG)\u2014what do we Know?. Pharm. Res. 33, 2239\u20132249 (2016).","journal-title":"Pharm. Res."},{"key":"33463_CR17","doi-asserted-by":"publisher","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","volume":"88","author":"Q Yang","year":"2016","unstructured":"Yang, Q. et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88, 11804\u201311812 (2016).","journal-title":"Anal. Chem."},{"key":"33463_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","volume":"9","author":"RP Garay","year":"2012","unstructured":"Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G. & Richette, P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 9, 1319\u20131323 (2012).","journal-title":"Expert Opin. Drug Deliv."},{"key":"33463_CR19","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","volume":"88","author":"B-M Chen","year":"2016","unstructured":"Chen, B.-M. et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal. Chem. 88, 10661\u201310666 (2016).","journal-title":"Anal. Chem."},{"key":"33463_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ejpb.2014.03.010","volume":"87","author":"R Liebner","year":"2014","unstructured":"Liebner, R. et al. Protein HESylation for half-life extension: Synthesis, characterization and pharmacokinetics of HESylated anakinra. Eur. J. Pharm. Biopharm. 87, 378\u2013385 (2014).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"33463_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/jps.24253","volume":"104","author":"R Liebner","year":"2015","unstructured":"Liebner, R., Meyer, M., Hey, T., Winter, G. & Besheer, A. Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra. J. Pharm. Sci. 104, 515\u2013526 (2015).","journal-title":"J. Pharm. Sci."},{"key":"33463_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0378-5173(01)00603-2","volume":"217","author":"AI Fernandes","year":"2001","unstructured":"Fernandes, A. I. & Gregoriadis, G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implication in its pharmacokinetics. Int. J. Pharm. 217, 215\u2013224 (2001).","journal-title":"Int. J. Pharm."},{"key":"33463_CR23","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1039\/c0py00406e","volume":"2","author":"M Barz","year":"2011","unstructured":"Barz, M., Luxenhofer, R., Zentel, R. & Vicent, M. J. Overcoming the PEG-addiction: Well-defined alternatives to PEG, from structure\u2013property relationships to better defined therapeutics. Polym. Chem. 2, 1900\u20131918 (2011).","journal-title":"Polym. Chem."},{"issue":"13","key":"33463_CR24","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/polym14132684","volume":"14","author":"P Pouyan","year":"2022","unstructured":"Pouyan, P., Cherri, M. & Haag, R. Polyglycerols as Multi-Functional Platforms: Synthesis and Biomedical Applications. Polymers, 14(13), 2684 (2022).","journal-title":"Polymers"},{"key":"33463_CR25","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.ddtec.2011.11.003","volume":"8","author":"K Licha","year":"2011","unstructured":"Licha, K. & Resch-Genger, U. Probes for optical imaging: New developments. Drug Discov. Today Technol. 8, e87-94 (2011).","journal-title":"Drug Discov. Today Technol."},{"key":"33463_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jconrel.2014.08.018","volume":"194","author":"HR Kr\u00fcger","year":"2014","unstructured":"Kr\u00fcger, H. R. et al. Imaging of doxorubicin release from theranostic macromolecular prodrugs via fluorescence resonance energy transfer. J. Control. Release 194, 189\u2013196 (2014).","journal-title":"J. Control. Release"},{"key":"33463_CR27","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1021\/bm5002608","volume":"15","author":"A Thomas","year":"2014","unstructured":"Thomas, A., M\u00fcller, S. S. & Frey, H. Beyond poly(ethylene glycol): Linear polyglycerol as a multifunctional polyether for biomedical and pharmaceutical applications. Biomacromol 15, 1935\u20131954 (2014).","journal-title":"Biomacromol"},{"key":"33463_CR28","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1002\/anie.200902672","volume":"49","author":"K Knop","year":"2010","unstructured":"Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49, 6288\u20136308 (2010).","journal-title":"Angew. Chem. Int. Ed."},{"key":"33463_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1021\/bm300103u","volume":"13","author":"F Wurm","year":"2012","unstructured":"Wurm, F., Dingels, C., Frey, H. & Klok, H.-A. Squaric acid mediated synthesis and biological activity of a library of linear and hyperbranched poly(glycerol)-protein conjugates. Biomacromol 13, 1161\u20131171 (2012).","journal-title":"Biomacromol"},{"key":"33463_CR30","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.xphs.2021.10.032","volume":"111","author":"M Tully","year":"2022","unstructured":"Tully, M. et al. Linear polyglycerol for N-terminal-selective modification of interleukin-4. J. Pharm. Sci. 111, 1642\u20131651 (2022).","journal-title":"J. Pharm. Sci."},{"key":"33463_CR31","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1021\/acs.biomac.0c01627","volume":"22","author":"M Tully","year":"2021","unstructured":"Tully, M. et al. Polyglycerol for half-life extension of proteins-alternative to PEGylation?. Biomacromol 22, 1406\u20131416 (2021).","journal-title":"Biomacromol"},{"key":"33463_CR32","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1021\/acs.biomac.1c00775","volume":"22","author":"N Hauptstein","year":"2021","unstructured":"Hauptstein, N. et al. Molecular insights into site-specific interferon-\u03b12a bioconjugates originated from PEG, LPG, and PEtOx. Biomacromol 22, 4521\u20134534 (2021).","journal-title":"Biomacromol"},{"key":"33463_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.05.060","author":"N Hauptstein","year":"2022","unstructured":"Hauptstein, N. et al. Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-\u03b12a. J. Control Release. https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.060 (2022).","journal-title":"J. Control Release."},{"key":"33463_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.chembiol.2005.01.017","volume":"12","author":"S-Y Chen","year":"2005","unstructured":"Chen, S.-Y. et al. Synthetic erythropoietic proteins: Tuning biological performance by site-specific polymer attachment. Chem. Biol. 12, 371\u2013383 (2005).","journal-title":"Chem. Biol."},{"key":"33463_CR35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cyto.2011.11.010","volume":"57","author":"C Kessler","year":"2012","unstructured":"Kessler, C. et al. Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities. Cytokine 57, 226\u2013237 (2012).","journal-title":"Cytokine"},{"key":"33463_CR36","doi-asserted-by":"publisher","first-page":"8514","DOI":"10.1038\/s41598-018-26936-x","volume":"8","author":"A Zemella","year":"2018","unstructured":"Zemella, A. et al. Cell-free protein synthesis as a novel tool for directed glycoengineering of active erythropoietin. Sci. Rep. 8, 8514 (2018).","journal-title":"Sci. Rep."},{"key":"33463_CR37","doi-asserted-by":"publisher","first-page":"12030","DOI":"10.1038\/s41598-017-12364-w","volume":"7","author":"M Stech","year":"2017","unstructured":"Stech, M. et al. Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates. Sci. Rep. 7, 12030 (2017).","journal-title":"Sci. Rep."},{"key":"33463_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082234","volume":"8","author":"AK Br\u00f6del","year":"2013","unstructured":"Br\u00f6del, A. K. et al. IRES-mediated translation of membrane proteins and glycoproteins in eukaryotic cell-free systems. PLoS ONE 8, e82234 (2013).","journal-title":"PLoS ONE"},{"key":"33463_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-4939-9121-1_4","volume":"1947","author":"A Zemella","year":"2019","unstructured":"Zemella, A., Richter, T., Thoring, L. & Kubick, S. A combined cell-free protein synthesis and fluorescence-based approach to investigate GPCR binding properties. Methods Mol. Biol. (Clifton, N. J.) 1947, 57\u201377 (2019).","journal-title":"Methods Mol. Biol. (Clifton, N. J.)"},{"key":"33463_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jbiotec.2012.08.020","volume":"164","author":"M Stech","year":"2012","unstructured":"Stech, M. et al. Production of functional antibody fragments in a vesicle-based eukaryotic cell-free translation system. J. Biotechnol. 164, 220\u2013231 (2012).","journal-title":"J. Biotechnol."},{"key":"33463_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/mps2020030","volume":"2","author":"L Thoring","year":"2019","unstructured":"Thoring, L., Zemella, A., W\u00fcstenhagen, D. & Kubick, S. Accelerating the Production of Druggable Targets: Eukaryotic Cell-Free Systems Come into Focus. Methods Protoc. 2(2), 30 (2019).","journal-title":"Methods Protoc."},{"key":"33463_CR42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/elsc.201400036","volume":"14","author":"M Stech","year":"2014","unstructured":"Stech, M., Hust, M., Schulze, C., D\u00fcbel, S. & Kubick, S. Cell-free eukaryotic systems for the production, engineering, and modification of scFv antibody fragments. Eng. Life Sci. 14, 387\u2013398 (2014).","journal-title":"Eng. Life Sci."},{"key":"33463_CR43","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41598-020-59634-8","volume":"10","author":"F Ramm","year":"2020","unstructured":"Ramm, F. et al. Mammalian cell-free protein expression promotes the functional characterization of the tripartite non-hemolytic enterotoxin from Bacillus cereus. Sci. Rep. 10, 2887 (2020).","journal-title":"Sci. Rep."},{"key":"33463_CR44","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/2302","volume":"5","author":"JC Cheetham","year":"1998","unstructured":"Cheetham, J. C. et al. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat. Struct. Biol. 5, 861\u2013866 (1998).","journal-title":"Nat. Struct. Biol."},{"key":"33463_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2005.06.001","volume":"214","author":"C Fruijtier-P\u00f6lloth","year":"2005","unstructured":"Fruijtier-P\u00f6lloth, C. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology 214, 1\u201338 (2005).","journal-title":"Toxicology"},{"key":"33463_CR46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/10915819309141598","volume":"12","author":"J Jang","year":"1993","unstructured":"Jang, J. Final report on the safety assessment of polyethylene glycols (PEGs)-6,-8,-32,-75,-150,-14M,-20M. J. Am. Coll. Toxicol. 12, 429\u2013457 (1993).","journal-title":"J. Am. Coll. Toxicol."},{"key":"33463_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5487\/TR.2015.31.2.105","volume":"31","author":"H-J Jang","year":"2015","unstructured":"Jang, H.-J., Shin, C. Y. & Kim, K.-B. Safety evaluation of polyethylene glycol (PEG) compounds for cosmetic use. Toxicol. Res. 31, 105\u2013136 (2015).","journal-title":"Toxicol. Res."},{"key":"33463_CR48","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","volume":"35","author":"T Shimizu","year":"2012","unstructured":"Shimizu, T. et al. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and pegylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol. Pharm. Bull. 35, 1336\u20131342 (2012).","journal-title":"Biol. Pharm. Bull."},{"key":"33463_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","volume":"112","author":"T Ishida","year":"2006","unstructured":"Ishida, T. et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 112, 15\u201325 (2006).","journal-title":"J. Control. Release"},{"key":"33463_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cncr.22739","volume":"110","author":"JK Armstrong","year":"2007","unstructured":"Armstrong, J. K. et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110, 103\u2013111 (2007).","journal-title":"Cancer"},{"key":"33463_CR51","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky, P. E. et al. Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res. Ther. 16, R60 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"33463_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/pharmaceutics12010015","volume":"12","author":"T-C Chang","year":"2019","unstructured":"Chang, T.-C. et al. Both IgM and IgG antibodies against polyethylene glycol can alter the biological activity of methoxy polyethylene glycol-epoetin beta in mice. Pharmaceutics 12, 25 (2019).","journal-title":"Pharmaceutics"},{"key":"33463_CR53","first-page":"363","volume-title":"Woodhead Publishing Series in Biomaterials","author":"S Abbina","year":"2018","unstructured":"Abbina, S. & Parambath, A. Engineering of biomaterials for drug delivery systems. In Woodhead Publishing Series in Biomaterials (ed. Parambath, A.) 363\u2013376 (Woodhead Publishing, Uk, 2018)."},{"key":"33463_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","volume":"244","author":"P Zhang","year":"2016","unstructured":"Zhang, P., Sun, F., Liu, S. & Jiang, S. Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. J. Control Release 244, 184\u2013193 (2016).","journal-title":"J. Control Release"},{"key":"33463_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/polym12020298","volume":"12","author":"TT Hoang-Thi","year":"2020","unstructured":"Hoang-Thi, T. T. et al. The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation. Polymers (Basel) 12, 298 (2020).","journal-title":"Polymers (Basel)"},{"key":"33463_CR56","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijpharm.2013.07.059","volume":"456","author":"AS Abu-Lila","year":"2013","unstructured":"Abu-Lila, A. S., Nawata, K., Shimizu, T., Ishida, T. & Kiwada, H. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int. J. Pharmaceut. 456, 235\u2013242 (2013).","journal-title":"Int. J. Pharmaceut."},{"key":"33463_CR57","doi-asserted-by":"publisher","first-page":"9135","DOI":"10.1016\/j.biomaterials.2012.09.007","volume":"33","author":"M Imran-ul-haq","year":"2012","unstructured":"Imran-ul-haq, M., Lai, B. F. L., Chapanian, R. & Kizhakkedathu, J. N. Influence of architecture of high molecular weight linear and branched polyglycerols on their biocompatibility and biodistribution. Biomaterials 33, 9135\u20139147 (2012).","journal-title":"Biomaterials"},{"key":"33463_CR58","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1021\/bm0504882","volume":"7","author":"RK Kainthan","year":"2006","unstructured":"Kainthan, R. K., Janzen, J., Levin, E., Devine, D. V. & Brooks, D. E. Biocompatibility testing of branched and linear polyglycidol. Biomacromol 7, 703\u2013709 (2006).","journal-title":"Biomacromol"},{"key":"33463_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1006\/abio.1996.9993","volume":"245","author":"OW Odom","year":"1997","unstructured":"Odom, O. W., Kudlicki, W., Kramer, G. & Hardesty, B. An Effect of polyethylene glycol 8000 on protein mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a method for eliminating this effect. Anal. Biochem. 245, 249\u2013252 (1997).","journal-title":"Anal. Biochem."},{"key":"33463_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF01748163","volume":"66","author":"K-U Eckardt","year":"1988","unstructured":"Eckardt, K.-U. et al. Evaluation of the stability of human erythropoietin in samples for radioimmunoassay. Klin. Wochenschr. 66, 241\u2013245 (1988).","journal-title":"Klin. Wochenschr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33463-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:03:00Z","timestamp":1681948980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33463-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33463"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33463-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6394"}}